Mupirocin Mounted Copper Nanoparticle Offered Augmented Drug Delivery against Resistant Bacteria

Aim: In present investigation, mupirocin coupled copper nanoparticles were synthesized to overwhelm drug resistance in Staphylococcus aureus, responsible for dermal skin infections. Materials and Methods: Mupirocin (Anclaima Pvt. Ltd. India), copper sulphate (Thermo Fisher Scientific, India), Tri sodium citrate (Nice chemicals, India) Copper nanoparticles were produced by size reduction method by using Copper Sulphate and Tri sodium citrate. CuNPs were merged into gel base of carbopol which was formed by hot method. Carbapol gel shows no phase separation. Results and Discussion: The particle size of CuNPs was found to be 413.0± 30.2nm. The % EE was found to be 65.2%. On description unilamellar, sphere-shaped vesicles with soft surface were detected under transmission electron microscopy. XRD of CuNPs was found out crystalline in nature. The zeta potential of nanoparticle shows less aggregation of particle with - 15.1 ± 3.69 mV value. The amount of copper content was measured 5.9 microgram/10 mg of nanoparticles. In vitro release study of Cu NPs shows 96.5% release of drug and show effective antibacterial activity against Staphylococcus aureus. Conclusion: Mupirocin copper nanoparticles were produced and show excellent antibacterial activity upon S. aureus.